MCID: BNR002
MIFTS: 38

Bone Resorption Disease

Categories: Bone diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Bone Resorption Disease

MalaCards integrated aliases for Bone Resorption Disease:

Name: Bone Resorption Disease 11 14
Bone Resorption 43 75

Classifications:



External Ids:

Disease Ontology 11 DOID:0080011
MeSH 43 D001862

Summaries for Bone Resorption Disease

Disease Ontology: 11 A bone remodeling disease that results in an abnormal decrease of bone density or mass.

MalaCards based summary: Bone Resorption Disease, also known as bone resorption, is related to paget disease of bone 5, juvenile-onset and osteopetrosis. An important gene associated with Bone Resorption Disease is MIR214 (MicroRNA 214), and among its related pathways/superpathways are MicroRNAs in cardiomyocyte hypertrophy and Mesenchymal Stem Cells and Lineage-specific Markers. The drugs Hyaluronic acid and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and spinal cord, and related phenotypes are limbs/digits/tail and skeleton

Wikipedia: 75 Bone resorption is resorption of bone tissue, that is, the process by which osteoclasts break down the... more...

Related Diseases for Bone Resorption Disease

Diseases related to Bone Resorption Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 620)
# Related Disease Score Top Affiliating Genes
1 paget disease of bone 5, juvenile-onset 32.4 TNFSF11 CALCA
2 osteopetrosis 32.4 TNFSF11 RUNX2 CTSK CALCA BGLAP ACP5
3 paget's disease of bone 32.4 TNFSF11 PTH CTSK CALCA BGLAP ACP5
4 osteitis fibrosa 32.4 SOST PTH CALCA BGLAP
5 glucocorticoid-induced osteoporosis 32.2 TNFSF11 SP7 SOST RUNX2 PTH MIR214
6 periodontitis 32.1 TNFSF11 RUNX2 MIR142 CTSK BGLAP ACP5
7 failure of tooth eruption, primary 32.1 SP7 PTH
8 osteoporosis 32.0 TNFSF11 SP7 SOST RUNX2 PTH MIR27A
9 bone disease 31.8 TNFSF11 SP7 SOST RUNX2 PTH MIR27A
10 rickets 31.7 PTH CALCA BGLAP
11 hyperparathyroidism 31.6 TNFSF11 SOST PTH CALCA BGLAP ACP5
12 mammary paget's disease 31.6 TNFSF11 SP7 SOST RUNX2 PTH CTSK
13 osteogenic sarcoma 31.5 TNFSF11 SP7 RUNX2 PTH MIR140 BGLAP
14 osteonecrosis 31.5 RUNX2 PTH BGLAP ACP5
15 osteoarthritis 31.5 TNFSF11 RUNX2 MIR140 CTSK BGLAP
16 myeloma, multiple 31.4 TNFSF11 MIR335 MIR27A MIR142 MIR140 BGLAP
17 periapical periodontitis 31.4 TNFSF11 SP7 RUNX2 CTSK BGLAP ACP5
18 secondary hyperparathyroidism 31.4 PTH CALCA BGLAP ACP5
19 bone giant cell tumor 31.3 TNFSF11 RUNX2 PTH CTSK CALCA ACP5
20 primary hyperparathyroidism 31.3 TNFSF11 SOST PTH CALCA BGLAP ACP5
21 hyperthyroidism 31.2 PTH CALCA BGLAP ACP5
22 chronic kidney disease 31.2 TNFSF11 SOST RUNX2 PTH CALCA BGLAP
23 osteomalacia 31.1 TNFSF11 SOST PTH CALCA BGLAP
24 pycnodysostosis 31.1 TNFSF11 SOST CTSK BGLAP ACP5
25 osteomyelitis 31.1 TNFSF11 CTSK CALCA ACP5
26 kidney disease 31.1 TNFSF11 SOST RUNX2 PTH CALCA BGLAP
27 hypercalcemia, infantile, 1 31.1 PTH CALCA
28 renal osteodystrophy 31.1 TNFSF11 PTH CALCA BGLAP ACP5
29 root resorption 31.1 TNFSF11 RUNX2 CALCA
30 spondyloarthropathy 1 31.0 TNFSF11 PTH BGLAP
31 exostosis 31.0 SOST RUNX2 BGLAP
32 ankylosis 30.9 TNFSF11 SP7 SOST RUNX2 BGLAP
33 bone cancer 30.9 MIR335 MIR29B1 MIR27A MIR23A MIR223 MIR214
34 sclerosteosis 1 30.9 SP7 SOST BGLAP
35 endosteal hyperostosis, autosomal dominant 30.9 TNFSF11 SP7 SOST PTH CTSK ACP5
36 hemiplegia 30.9 CALCA BGLAP ACP5
37 hypophosphatemia 30.9 SOST PTH BGLAP
38 sclerosteosis 30.8 TNFSF11 SP7 SOST RUNX2 PTH CTSK
39 hypoparathyroidism 30.8 PTH CALCA BGLAP
40 hypervitaminosis d 30.8 PTH CALCA
41 brittle bone disorder 30.7 TNFSF11 SP7 SOST RUNX2 PTH MIR214
42 osteochondrodysplasia 30.7 TNFSF11 SP7 SOST RUNX2 PTH MIR140
43 dental pulp necrosis 30.7 TNFSF11 RUNX2 BGLAP
44 bone inflammation disease 30.7 TNFSF11 MIR335 MIR29B1 MIR27A MIR23A MIR223
45 osteopetrosis, autosomal dominant 2 30.7 TNFSF11 CTSK BGLAP ACP5
46 chronic apical periodontitis 30.6 TNFSF11 RUNX2
47 oral squamous cell carcinoma 30.6 MIR29B1 MIR27A MIR23A MIR223 MIR214 MIR188
48 renal cell carcinoma, nonpapillary 30.6 MIR335 MIR29B1 MIR27A MIR23A MIR223 MIR214
49 scoliosis 30.6 TNFSF11 RUNX2 CTSK BGLAP ACP5
50 type 2 diabetes mellitus 30.6 PTH MIR335 MIR27A MIR23A MIR223 MIR214

Graphical network of the top 20 diseases related to Bone Resorption Disease:



Diseases related to Bone Resorption Disease

Symptoms & Phenotypes for Bone Resorption Disease

MGI Mouse Phenotypes related to Bone Resorption Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 limbs/digits/tail MP:0005371 9.61 ACP5 CTSK MIR140 MIR188 PTH RUNX2
2 skeleton MP:0005390 9.36 ACP5 BGLAP CALCA CTSK MIR140 MIR188

Drugs & Therapeutics for Bone Resorption Disease

Drugs for Bone Resorption Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
2
Adalimumab Approved, Experimental Phase 4 331731-18-1
3
Denosumab Approved Phase 4 615258-40-7
4
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
5
Ibandronate Approved, Investigational Phase 4 114084-78-5 60852
6
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850 155817470
7
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
8 Antirheumatic Agents Phase 4
9 Anti-Inflammatory Agents Phase 4
10 Trace Elements Phase 4
11 Micronutrients Phase 4
12 Diphosphonates Phase 4
13 Vitamins Phase 4
14 Calciferol Phase 4
15 Calcium, Dietary Phase 4
16 Hormones Phase 4
17
Calcium Nutraceutical Phase 4 7440-70-2 271
18
Zoledronic acid Approved Phase 2, Phase 3 118072-93-8 68740
19 Anesthetics Phase 3
20 Liver Extracts Phase 2, Phase 3
21
Simvastatin Approved Phase 2 79902-63-9 54454
22
Saracatinib Investigational Phase 2 379231-04-6 10302451
23 Whey Protein Phase 1, Phase 2
24 Antimetabolites Phase 2
25 Hypolipidemic Agents Phase 2
26 Anticholesteremic Agents Phase 2
27 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
28 Lipid Regulating Agents Phase 2
29 Aromatase Inhibitors Phase 1, Phase 2
30
Flurbiprofen Approved, Investigational Phase 1 5104-49-4 3394
31
Celecoxib Approved, Investigational Phase 1 169590-42-5 2662
32
Ibuprofen Approved Phase 1 15687-27-1 3672
33 Analgesics Phase 1
34 Cyclooxygenase Inhibitors Phase 1
35 Cyclooxygenase 2 Inhibitors Phase 1
36 Anti-Inflammatory Agents, Non-Steroidal Phase 1
37 Analgesics, Non-Narcotic Phase 1
38 Pharmaceutical Solutions Phase 1
39
Povidone-iodine Approved 25655-41-8
40
Sodium citrate Approved, Investigational 68-04-2 23431961
41
Lidocaine Approved, Vet_approved 137-58-6 3676
42
Dopamine Approved 62-31-7, 51-61-6 681
43
Metamfetamine Approved, Illicit, Withdrawn 537-46-2 10836
44
Amoxicillin Approved, Vet_approved 26787-78-0 33613
45
Chlorhexidine Approved, Vet_approved, Withdrawn 55-56-1 2713 9552079
46
Calcium carbonate Approved, Investigational 471-34-1
47
Miconazole Approved, Investigational, Vet_approved 22916-47-8 4189
48
Clotrimazole Approved, Vet_approved 23593-75-1 2812
49
Salicylic acid Approved, Investigational, Vet_approved 69-72-7 338
50
Glycolic acid Approved, Investigational 79-14-1 757

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Hyaluronic Acid Effect on Xenogenic Bone Substitutes Healing During Ridge Preservations: A Radiological and Histomorphometric Study Unknown status NCT04377256 Phase 4
2 Bone Resorption, Osteoclastogenesis and Adalimumab Unknown status NCT02035800 Phase 4 Adalimumab
3 Evaluation of Anterior Alveolar Ridge Reconstruction With Allogenic Bone Plate and Autogenous Cortical Bone Chips: A Radiographic and Histological Clinical Study Completed NCT04324697 Phase 4
4 The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty: A Randomised, Double Blind, Placebo Controlled Clinical Trial Completed NCT02760979 Phase 4 Denosumab;Placebo
5 Effects of 1% Sodium Alendronate in Non Surgical Periodontal Therapy on Clinical and Tomographical Parameters: a Randomized Placebo Controlled 6-month Clinical Trial Completed NCT02470611 Phase 4 Sodium alendronate
6 A Randomized, Double-blind, Placebo-controlled Study to Determine Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once Monthly Ibandronate in the Treatment of Postmenopausal Osteoporosis Completed NCT00303485 Phase 4 Placebo;Vitamin D and calcium supplementation;ibandronate [Bonviva/Boniva]
7 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
8 A Method for Measuring Volume Changes of the Alveolar Ridge During Dental Implantation Using 3D Scanning Recruiting NCT03089619 Phase 4 Human-Spongiosa
9 Ridge Preservation Comparing the Clinical and Histologic Healing of Two Different Putty Bone Grafts Recruiting NCT05484492 Phase 4
10 COMPARATIVE EVALUATION OF BIOACTIVE GLASS PUTTY AND PLATELET RICH FIBRIN IN THE TREATMENT OF HUMAN PERIODONTAL INTRABONY DEFECTS- A CLINICAL AND RADIOGRAPHICAL STUDY" Completed NCT02982681 Phase 3 Platelet rich fibrin;Bioactive Glass
11 Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation Completed NCT00297830 Phase 2, Phase 3 Zoledronic acid;Alendronate
12 Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy Completed NCT00172055 Phase 3 Zoledronic acid
13 Impact of a Protein Supplement on Bone Mass in Older Men and Women Completed NCT00421408 Phase 1, Phase 2
14 Restoration of Immediate Peri-implant Defect by Simvastatin: a Controlled Clinical and Cone Beam Computed Tomography Study Completed NCT04803500 Phase 2 Simvastatin;Placebo
15 Teh Histomorphometric Study of Nanocrystalline Hydroxyapatite (Nano Bone) Wif Alendronate in Teh Preservation of Teh Tooth Socket Completed NCT03980847 Phase 2 Alendronate 20 mg
16 The Effect Of Lasofoxifene On Local Mediators Of Bone Resorption In The Prevention Of Postmenopausal Osteoporosis Completed NCT00674453 Phase 2 Lasofoxifene
17 Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005) Completed NCT00533650 Phase 2 MK0429
18 A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease. Completed NCT00558272 Phase 2 AZD0530;Zoledronic Acid
19 Bone Quality and Quantity in the Maxillary Sinus Grafted With Xenograft or Synthetic Bone Substitute: A Radiographic and Histomorphometric Randomized Controlled Clinical Study Recruiting NCT04433117 Phase 2
20 Feasibility of Bisphosphonate Use on Sleeve Gastrectomy Associated Bone Loss: Healthy Body, Healthy Bones Trial Active, not recruiting NCT04279392 Phase 1, Phase 2 Zoledronic Acid 5 mg/Bag 100 ml Inj;Placebos
21 A Phase I/II Randomized, Double-blind, Controlled Study to Evaluate Efficacy and Safety of Vitamin D on Bone Mineral Density and Markers of Bone Resorption in Aromatase Inhibitor-induced Bone Loss in Women With Breast Cancer. Terminated NCT00904423 Phase 1, Phase 2 Vitamin D
22 Health of Young European Families and Fish Consumption Unknown status NCT00315770 Phase 1
23 Evaluation of Efficacy of Injectable Platelet-Rich Plasma (PRP) in Reducing Alveolar Bone Resorption Following Rapid Maxillary Expansion (RME): A Cone Beam Computed Tomography (CBCT) Assessment Completed NCT03028038 Phase 1 Platelet Rich Plasma;No Platelet Rich Plasma
24 A Double-Blind, Placebo-Controlled, Once-Weekly, Multiple-Dose Study to Investigate the Safety, Tolerability, Plasma Concentration Profile and Effects on Biochemical Markers of Bone Resorption of MK0822 in Healthy Postmenopausal Female Subjects Completed NCT00770159 Phase 1 odanacatib;Comparator: placebo to MK0822
25 The Effects of Non-steroidal Anti-inflammatory Drugs on Circulating Markers of Bone Metabolism Following Plyometric Exercise in Humans Recruiting NCT05512013 Phase 1 Ibuprofen 800 mg;Celecoxib 200mg;Flurbiprofen 100 mg;Placebo
26 Autogenous Mesenchymal Stem Cell Culture-Derived Signalling Molecules as Enhancers of Bone Formation in Bone Grafting Not yet recruiting NCT04998058 Phase 1
27 Alveolar Ridge Preservation in Mandibular Molars Using Mixture of Autogenous Bone & Anorganic Bovine Bone (ABB) Versus Anorganic Bovine Bone Alone Versus Absorbent Gelatin Sponge Unknown status NCT03584984
28 Assessment of Vertical Bone Augmentation Using Autogenous Onlay Versus Inlay Grafting Techniques With Simultaneous Implant Placement in the Anterior Maxillary Area on Patient's Esthetic Satisfaction : A Randomized Clinical Trial Unknown status NCT03052387
29 Posterior Maxillary Ridge Augmentation With Sinus Lift Using Mineralized Plasmatic Matrix Versus Autogenous Bone Graft (A Randomized Clinical Trial Comparative Study) Unknown status NCT03014388
30 Clinical Evaluation and Primary Stability of Early Loaded Implants With Sandblasted and Acid-etched Surface Versus Implants With SA Surface Modified With pH Buffering Agent: a Multicenter Randomized Controlled Trial Unknown status NCT04073654
31 Ridge Augmentation in Atrophic Anterior Maxillary Ridges With Native Collagen Membrane and Anorganic Bovine Bone Derived Mineral With and Without Particulated Autogenous Bone Chips Unknown status NCT03731416
32 Evaluation of Computer-Guided Versus Conventional Simultaneous Implant Placement With Ridge Augmentation Using an Autogenous Bone Ring Graft With PRF on Patient's Esthetic Satisfaction Unknown status NCT03049137 Platelet-rich fibrin (PRF)
33 Effect of Citric Acid Demineralization on Autogenous Bone Blocks Consolidation in Humans: Qualitative, Quantitative and Immunohistochemical Analysis Unknown status NCT03357068
34 Clinical Assessment of Buccal Plate Expansion Technique Versus Guided Bone Regeneration Technique in Socket Preservation in The Esthetic Zone: A Randomized Controlled Clinical Trial Unknown status NCT03065803
35 Implant Insertion in Defective Anterior Maxillary Ridge Augmented Using Mineralized Plasmatic Matrix Versus Autogenous Bone Graft Unknown status NCT03007069
36 Study of Tooth Alveolar Extraction Socket Anatomy and Its Relation to Alveolar Post-extraction Changes Unknown status NCT01963884
37 Clinical, Radiographic and Histomorphometric Comparison of Autogenous Demineralized Dentin Matrix Versus Bovine-Derived Xenograft for Socket Preservation: A Randomised Controlled Clinical Trial Unknown status NCT04239378
38 Comparative Evaluation of Novel Ribose Cross Linked Volumising Collagen Matrix v/s Ribose Cross Linked Resorbable Collagen Membrane and Bone Graft for Lateral Ridge Augmentation Around Implants: A Randomised Controlled Clinical Trial Unknown status NCT04197128
39 Clinical Evaluation of the Effect of Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla. A Randomized Controlled Clinical Trial Unknown status NCT03220815
40 Standard Implants With Bone Regeneration vs Short Implants (Implantes Convencionales Con regeneración ósea vs. Implantes Cortos) Unknown status NCT03524885
41 Clinical Evaluation of the Effect of Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla. A Randomized Controlled Clinical Trial Unknown status NCT03212820
42 Evaluation of Vertical Bone Augmentation Using Anterior Maxillary Segmental Sandwich Osteotomy: Simultaneous Versus Delayed Implant Placement, A Randomized Controlled Trial Unknown status NCT04022538
43 Clinical Evaluation Of Dental Implants Stability Placed In Healed Bony Sites Following Over-drilling Compared To Conventional-Drilling Protocol: A Randomized Controlled Trial. Unknown status NCT03250949
44 Clinical Evaluation of the Effect of Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla. A Randomized Controlled Clinical Trial Unknown status NCT03220789
45 Alveolar Ridge Preservation In Mandibular Molars Using Mixture Of Anorganic Bovine Bone(ABB) And Autogenous Particulate VS Mixture Of Injectable Platelets Rich Fibrin, ABB And Autogenous Particulates (Sticky Bone). Unknown status NCT03584997
46 Influence of Soft Tissue Thickness and Insertion Depth of Platform Switched Implants on Crestal Bone Level Alteration Unknown status NCT02867982 prophylactic antibiotics
47 A Prospective, Randomized-controlled Study of the Effect of a Chlorhexidine Based Gel on the Internal Implant Surface Treatment on the Reduction of Bacterial Load and on the Regressive Bone Modelling. Unknown status NCT03431766
48 Bone Changes Assessment in Screw-Retained Maxillary Implant Supported Complete Denture With Electric Welded Metal Framework Versus Cast One (Randomized Control,Split Mouth Trial) Unknown status NCT04548258
49 Clinical Assessment of Buccal Bone Resorption in Immediate Implants in Thin and Thick Buccal Plates of Bone and Its Implication on Esthetics. A Controlled Clinical Trial Unknown status NCT04630665
50 Role of Light Emitting Diode on Implant Stability, Bone Resorption and Analgesia Post Dental Implant Placement Unknown status NCT01097499

Search NIH Clinical Center for Bone Resorption Disease

Cochrane evidence based reviews: bone resorption

Genetic Tests for Bone Resorption Disease

Anatomical Context for Bone Resorption Disease

Organs/tissues related to Bone Resorption Disease:

MalaCards : Bone, Prostate, Spinal Cord, Breast, Liver

Publications for Bone Resorption Disease

Articles related to Bone Resorption Disease:

# Title Authors PMID Year
1
miR-30a-5p inhibits osteogenesis and promotes periodontitis by targeting Runx2. 62
34635105 2021
2
[Effect of inhibition of Porphyromonas endodontalis on osteoblast differentiation]. 62
34693425 2021
3
Zoledronic acid : Treatment option for Gorham-Stout disease. 62
30280236 2018
4
CB(2) and TRPV(1) receptors oppositely modulate in vitro human osteoblast activity. 62
26117426 2015
5
Role of exopolysaccharide in Aggregatibacter actinomycetemcomitans-induced bone resorption in a rat model for periodontal disease. 62
25706999 2015
6
Bone biomarkers of ovariectomised rats after leptin therapy. 62
23731039 2013
7
New approaches to the treatment of osteoporosis. 62
10959765 2000
8
The effect of rectally administered steroids on bone turnover: a comparative study. 62
9570255 1998
9
Rectal steroids suppress bone formation in patients with colitis. 62
9042994 1997
10
Flurbiprofen: a potent inhibitor of alveolar bone resorption in beagles. 62
3969553 1985

Variations for Bone Resorption Disease

Expression for Bone Resorption Disease

Search GEO for disease gene expression data for Bone Resorption Disease.

Pathways for Bone Resorption Disease

GO Terms for Bone Resorption Disease

Cellular components related to Bone Resorption Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.98 BGLAP CALCA CTSK MIR133A1 MIR140 MIR142
2 RISC complex GO:0016442 9.62 MIR550A1 MIR335 MIR29B1 MIR27A MIR23A MIR223
3 extracellular vesicle GO:1903561 9.46 MIR29B1 MIR27A MIR23A MIR214

Biological processes related to Bone Resorption Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.99 PTH MIR29B1 MIR27A MIR214 MIR140
2 ossification GO:0001503 9.97 TNFSF11 SOST RUNX2 CALCA BGLAP
3 miRNA-mediated gene silencing GO:0035195 9.96 MIR133A1 MIR140 MIR142 MIR188 MIR214 MIR223
4 positive regulation of gene expression GO:0010628 9.93 TNFSF11 RUNX2 PTH MIR29B1 MIR27A MIR23A
5 cellular response to zinc ion starvation GO:0034224 9.88 SP7 CTSK BGLAP
6 bone resorption GO:0045453 9.86 ACP5 CTSK PTH TNFSF11
7 negative regulation of BMP signaling pathway GO:0030514 9.84 SOST MIR214 MIR140
8 negative regulation of cell migration GO:0030336 9.83 MIR335 MIR29B1 MIR214 MIR133A1
9 negative regulation of vascular associated smooth muscle cell proliferation GO:1904706 9.67 MIR223 MIR214 MIR140 MIR133A1
10 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.65 MIR223 MIR214 MIR140
11 negative regulation of SMAD protein signal transduction GO:0060392 9.61 MIR140 MIR23A MIR27A
12 negative regulation of BMP secretion GO:2001285 9.49 MIR214 MIR140
13 positive regulation of Fas signaling pathway GO:1902046 9.46 MIR27A MIR23A
14 miRNA-mediated gene silencing by mRNA destabilization GO:0035279 9.02 MIR27A MIR23A MIR223 MIR214 MIR140

Molecular functions related to Bone Resorption Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.61 MIR335 MIR29B1 MIR27A MIR23A MIR223 MIR214
2 mRNA base-pairing translational repressor activity GO:1903231 9.32 MIR335 MIR29B1 MIR27A MIR23A MIR223 MIR214

Sources for Bone Resorption Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....